Priority review changes FDA's target for reviewing a marketing application. It does not change the legal standard for approval and does not mean the application has already been judged successful.
The clearest way to understand the status is to place it late in the development timeline: clinical studies have generated an application, the sponsor has submitted it, and FDA has decided the application merits an expedited review goal.
What qualifies for priority review
FDA can designate an application for priority review when, if approved, the product would provide a significant improvement in safety or effectiveness for a serious condition compared with available applications or products. Factors can include increased effectiveness, prevention of serious outcomes, substantial safety improvement, or improved treatment compliance expected to produce better outcomes.
Certain statutory provisions and vouchers can also lead to priority review. A voucher-based review does not itself mean FDA has concluded that the product offers a significant clinical improvement.
The route to priority status should therefore be identified when it matters to the claim.
The review clock is a goal, not a guarantee
For new molecular entity drug applications and original biologics license applications, FDA's performance goals distinguish priority from standard review timelines. The commonly summarized goals are six months for priority review and ten months for standard review, measured from the filing date under current user-fee conventions.
The filing date is not always the original submission date because FDA first performs a filing review. Major amendments can extend the goal date. Inspections, manufacturing deficiencies, missing data, advisory committee scheduling, or safety issues can also affect timing.
A public target action date is often called a PDUFA date. It is a performance goal for agency action, not a promised approval date.
Possible actions include more than approval
By the goal date, FDA may approve the application or issue a complete response letter explaining why the application cannot be approved in its present form. A complete response can cite clinical, statistical, manufacturing, inspection, labeling, or other deficiencies.
Priority review therefore predicts agency resource allocation and timeline, not the direction of the decision.
Do not confuse four expedited terms
- Fast track: a development designation for serious conditions and unmet need.
- Breakthrough therapy: a development designation based on preliminary clinical evidence of substantial improvement.
- Priority review: an expedited review goal for a submitted application.
- Accelerated approval: an approval pathway that can rely on a surrogate or intermediate endpoint reasonably likely to predict benefit.
A single program may receive all four, some, or none. Each has its own criterion and date.
Priority review does not lower the approval standard
FDA still evaluates whether the application provides the evidence required for the proposed indication and whether manufacturing, labeling, and benefit-risk support approval. The agency directs additional attention and resources to complete that evaluation sooner.
“Expedited” should not be rewritten as “less rigorous.” The evidence package can differ because of disease context and pathway, but priority review itself is a timing designation.
Public announcements need a source hierarchy
Sponsors generally announce that FDA accepted an application and granted priority review, often with a target action date. FDA may later publish approval documents, an advisory committee calendar, or a complete response outcome.
Before approval, the sponsor announcement may be the primary public source for the priority designation. After action, Drugs@FDA, FDA press materials, and the approved label are more authoritative for the outcome.
Keep “application accepted for review” separate from “application approved.” Filing acceptance indicates sufficient completeness for substantive review, not satisfaction of the approval standard.
Read the exact application scope
Priority review attaches to an application or supplement, not to every use of a molecule. An already-approved product may receive priority review for a new indication, population, formulation, or labeling supplement.
A careful summary states:
- application type;
- product and formulation;
- proposed indication;
- priority-review basis if known;
- target action date;
- final action and date when available.
Without the indication, a headline can make routine review of a new use sound like first approval of the product.
A compact fact-checking workflow
- Find the dated sponsor or FDA announcement.
- Confirm whether FDA accepted the filing and assigned priority review.
- Note whether the status came through clinical-improvement criteria or a voucher.
- Record the target action date as a goal, not an outcome.
- Check advisory committee materials if a meeting occurs.
- After the date, search Drugs@FDA and FDA announcements for the action.
- Read the final label before describing the approved population or claim.
Accurate language
Before a decision:
FDA accepted the application for priority review, setting an expedited target for agency action. The product is not yet approved for the proposed indication.
After a decision:
Following priority review, FDA approved the product for the indication described in the current label.
The words “following priority review” preserve the timing mechanism without implying that priority status caused or guaranteed approval.
Bottom line
Priority review is a commitment to a shorter FDA review goal for a qualifying marketing application. It says nothing certain about the final outcome, does not lower the approval standard, and should always be tied to the exact application and indication under review.
Sources
- U.S. Food and Drug Administration. Priority Review.
- U.S. Food and Drug Administration. Expedited Programs for Serious Conditions, Drugs and Biologics.
- U.S. Food and Drug Administration. PDUFA Performance Goals and Procedures.
- U.S. Food and Drug Administration. Drugs@FDA.
- U.S. Food and Drug Administration. Complete Response Letter Final Rule.
Continue reading
Editorial responsibility and corrections
Published by Serum Research. Sources checked October 1, 2026. This is educational material; no independent scientific, clinical, statistical, analytical, or regulatory review is claimed. Read how we review evidence or send a correction.
For Research Use Only. Not for Human Consumption. This page does not provide instructions for medical use or establish the identity, quality, safety, or equivalence of a catalog material.